www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

March 21, 2019

PDF Version

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions under securities identification code (ISIN) DK0060027142 / LEI code: 529900SGCREUZCZ7P020. The announcement is based on the allotments of share options and performance shares which ALK has allocated to the following persons with a duty to report on 21 March 2019 in accordance with the incentive pay guidelines adopted at the Company’s annual general meeting on 13 March 2019:

 

Name
 

Position
 

Transaction
 

Number
Market value DKK 1,000
Carsten HellmannPresident & CEOShare options, granted6,266 
  Performance shares, allocated1,364 
Total   2,925


 

Name
 

Position
 

Transaction
 

Number
Market value DKK 1,000
Henrik JacobiMember ofShare options, granted2,653 
 Board of ManagementPerformance shares, allocated577 
Total   1,238


 

Name
 

Position
 

Transaction
 

Number
Market value, DKK 1,000
Søren JelertMember of
Board of Management
Share options, granted
Share options (March 2017), granted
2,136
1,669
 
  Performance shares, allocated
Performance shares (March 2017), allocated
465
321
 
Total   1,686


 

Name
 

Position
 

Transaction
 

Number
Market value DKK 1,000
Søren NiegelMember ofShare options, granted2,174 
 Board of ManagementPerformance shares, allocated473 
Total   1,014

The shares are traded at NASDAQ Copenhagen.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Attachment

  • FM_09_19UK_21032019
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved